A Comparative Review of Waivers Granted in Pediatric Drug Development by FDA and EMA From 2007-2013

Therapeutic Innovation and Regulatory Science - United States
doi 10.1177/2168479016646809
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Correction To: FDA and EMA Biosimilar Approvals

Journal of General Internal Medicine
Internal Medicine
2019English

From the FDA: Expanded Use Granted for Implantable Defibrillators

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1996English

Preclinical Efficacy in Therapeutic Area Guidelines From FDA and EMA: A Cross-Sectional Study

British Journal of Pharmacology
Pharmacology
2018English

From the FDA: Proper Pediatric Drug Dosing to Be Made Readily Available

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1995English

Drug Development Process and Novel Drugs Approved by FDA for 2017 -18

Applied Clinical Research, Clinical Trials and Regulatory Affairs
2018English

New FDA Drug Approval Policies and HIV Vaccine Development.

American Journal of Public Health
EnvironmentalPublic HealthOccupational Health
1990English

From the FDA: Epilepsy Drug Approved

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1994English

Role of Model‐Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling

Journal of Clinical Pharmacology
Pharmacology
2019English

Pnd115 - A Comparison of Fda and Ema Guidance on Medicines for the Treatment of Alzheimer’s Disease

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy